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CONCLUSIONS: Given that ChHD affects almost one in ﬁve
MCO members, its negative impact on members’ QoL, work and
activity impairment measures is signiﬁcant and should be con-
sidered by MCOs and employers.
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OBJECTIVE: Psoriasis is a common disease with profound
impact on many facets of life; there is physical impairment as
well as reductions in quality of life deﬁned by psychological,
social, sexual and ﬁnancial parameters. Work productivity,
another important component of patients’ overall well-being, has
also been reported to be impacted by psoriasis. The objective of
this study was to determine whether there exists a relationship
between clinical severity of psoriasis and work productivity.
METHODS: To quantify the impact of psoriasis on work pro-
ductivity, 90 patients were surveyed in a clinic setting. Three
severity groups were created based on Psoriasis Area and Sever-
ity Index (PASI) scores: mild <10, moderate = 10–20, and severe
>20. Work impairment was measured using the Work Produc-
tivity Assessment Index (WPAI); physical and mental health 
statuses were assessed using the SF-8; Anxiety/Depression was
assessed using the HADS; other health and employment infor-
mation were also collected. RESULTS: One-third of all subjects
were unemployed at the time of the study with 16.7% of these
subjects (5.5% of all 90 subjects) reporting that they were unem-
ployed because of their psoriasis. A greater percentage of patients
in the moderate and severe groups attributed their unemploy-
ment to psoriasis (33% for each), compared with the mild group
(9.5%). There was a trend toward increasing impairment while
at work with increasing psoriasis severity (severe 24.4%, mod-
erate 17.7% and mild 13.5%). With respect to the percent with
activity impairment, there was a statistically signiﬁcant differ-
ence between the severe group (42%) and the mild group
(20.2%)[all p < 0.05]. CONCLUSIONS: Psoriasis is associated
with work productivity impairment, and the degree of work
impact, missed work, physical and mental health condition and
anxiety/depression status tends to be greater in patients with
more severe skin involvement. These ﬁndings support the need




DEVELOPING MARKOV-MODEL INCLUDING TOBACCO-
ASSOCIATED DISEASES TO EVALUATE SMOKING CESSATION
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Up to now, there are few economic analyses which construct
models taking account of tobacco-associated diseases in Japan.
OBJECTIVES: To develop Markov-model, including various
tobacco-associated diseases to evaluate effects of nicotine-
replacement therapy (NRT) and smoking cessation guidance
therapy. METHODS: To identify various tobacco-associated 
diseases and markov transition probabilities, we organized a
committee including expert physicians. With expert interview,
we developed a Markov-model. RESULTS: We identiﬁed 19
tobacco-associated diseases as major results of smoking, accord-
ing to “Health Risk Appraisal”. The 19 diseases are as follows;
10 cancers—oropharyngeal cancer, esophageal cancer, gastric
cancer, hepatic cancer, rectal cancer, pancreatic cancer, lung
cancer, cervical cancer, renal cancer and bladder cancer; 
4 cardiovascular diseases—hypertensive heart disease, ischemic
heart disease, aneurysm and apoplexy; and 5 other diseases—
pneumonia, chronic bronchitis, asthma, gastric ulcer and cir-
rhosis. Tobacco is thought to increase incidence rate of those 19
diseases. We constructed four node Markov model, “Success (of
smoking cessation)” “Failure” “Death” and “Sick”. “Sick” node
consists of 19 diseases. We also considered a combination of
major diseases. In order to avoid many branches, we settled the
transition probabilities of diseases as a cumulative function of
incidence of each disease. The main assumptions are as follows;
1) Only one disease occurs during each cycle; 2) The risk of each
disease increases as cumulative tobacco consumption increases;
and 3) Smoking affects the incidence rate of the 19 diseases but
does not affect mortality rate from those diseases. One cycle 
in Markov chain is set to 5 year. For future cost-effectiveness
analysis of smoking cessation therapy, we set cost as well as 
transition probability on each branch. CONCLUSIONS: We
developed Markov-model, including various tobacco-associated
disease. In the future, we will take cost-effectiveness analysis to
evaluate smoking cessation therapy using this model.
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OBJECTIVES: The “Smoking Effects Inventory” (SEI) assesses
the degree to which subjects experience both desirable and aver-
sive effects from smoking. To date, no formal psychometric
analyses of the SEI have been published. We therefore tested the
validity and reliability of the pre-speciﬁed grouping of items on
the SEI. METHODS: Data came from three Phase II clinical
trials (n = 626, n = 627, n = 312) of varenicline, developed for
smoking cessation, using an adapted version of the SEI with 12
items (one item on enjoying smoking was added). Each item was
scored on a seven-point scale (one = “Not at all” to seven =
“Extremely”) in response to the experience of the reinforcing
effects of smoking. The pre-speciﬁed domains and single-item
scales were Satisfaction (satisfaction, good taste, enjoying
smoking); Psychological Reward (calming, feeling awake, reduc-
ing irritability, helping concentration, reducing hunger); Aversion
(dizziness, nausea); Enjoyment of Respiratory Tract Sensations;
and Craving Reduction. Conﬁrmatory factor analyses and inter-
nal consistency reliability analyses (Cronbach’s alpha) on multi-
item domains were performed at baseline in each of the three
trials. RESULTS: The postulated multidimensional framework of
the SEI was supported by conﬁrmatory factor analysis in each of
the three studies. Comparative ﬁt indexes (CFI) and non-normed
ﬁt indexes (NNFI) in the three trials exceeded 0.90 (CF = 0.94,
0.95, 0.94; NNFI = 0.92, 0.93, 0.92). Cronbach’s alpha exceeded
0.80 in the three studies for the Satisfaction domain (Cronbach’s
alpha: 0.82, 0.85, 0.84) and the Psychological Reward domain
(0.84, 0.82, 0.83) but was less than 0.60 for the Aversion domain
(0.50, 0.55, and 0.56). CONCLUSION: The validity of the pos-
tulated multidimensional framework of the SEI is conﬁrmed and
supported by the data. Although reliability (internal consistency)
of the Aversion domain was not high, excellent reliability was
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evident on the Satisfaction domain and the Psychological
Reward domain.
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OBJECTIVES: The 10-item version of the 32-item Questionnaire
of Smoking Urges (the QSU-brief) provides a multidimensional
measure of craving to smoke. Previous research from a factor
analysis of the QSU-brief supported a two-factor structure with
Factor 1 measuring “a strong desire and intention to smoke 
with smoking perceived as rewarding” and Factor 2 measuring
“demonstrating anticipation of relief from negative affect and an
urgent desire to smoke”. We conducted an independent investi-
gation of the QSU-brief to assess the validity and reliability of
the proposed two-factor structure. METHODS: Data came from
a seven-week Phase II clinical trial (n = 626) of varenicline devel-
oped for smoking cessation. The two pre-speciﬁed domains from
previous research were Factor 1 (5 items) and Factor 2 (3 items).
Factor analyses and internal consistency reliability analyses
(Cronbach’s alpha) were conducted during occasions when
varying levels of craving intensity might be expected (baseline,
Week 2, and Week 4). RESULTS: The hypothesized multidi-
mensional framework of the QSU-brief was supported by con-
ﬁrmatory factor analysis at each of the three occasions (baseline,
Week 2, Week 4). Comparative ﬁt indexes (CFI) and non-normed
ﬁt indexes (NNFI) exceeded 0.90 (CFI = 0.97, 0.95, 0.96; NNFI
= 0.96, 0.93, 0.95). Values of Cronbach’s alpha exceeded 0.75
on Factor 1 (0.90, 0.89, 0.90) and Factor 2 (0.76, 0.78, 0.85),
as well as on the Total Score of 10 items (0.92, 0.93, 0.93).
CONCLUSION: The validity and reliability of the postulated
two dimensional structure of self-reported craving as measured
by the QSU-brief is conﬁrmed.
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OBJECTIVES: To assess the cost-effectiveness of 18-month
treatment with clopidogrel versus aspirin in high-risk patients
with a recent history of Ischemic Stroke (IS) or Transient
Ischemic Attack (TIA) in four European countries: Belgium,
France, Switzerland, and UK. METHODS: We developed a
Markov model based on patients with IS or TIA in the previous
90 days (median 15 days) who were treated with clopidogrel in
the MATCH trial and followed prospectively for the occurrence
of recurrent IS or TIA, myocardial infarction (MI), other car-
diovascular death, life threatening bleeding, or major bleeding.
The event rates for IS and TIA patients treated with aspirin were
derived from a Cochrane review comparing clopidogrel and
aspirin by using a relative risk increase (RRI) of 1.11 for serious
vascular events (all strokes, MI, cardiovascular deaths). For
major bleedings with aspirin vs. clopidogrel, we used a RRI of
1.12 (CAPRIE trial). Death rates for other causes were country
speciﬁc and adjusted for this population. Lifetime perspective
was chosen and discount rates were applied according to the
local guidelines. RESULTS: Eighteen-month treatment with
clopidogrel compared to aspirin was associated with a gain in
quality adjusted life years (QALY) ranging from 31 years/1000
patients in the UK to 36 years/1000 patients in Belgium. 
The incremental cost per patient varied from 487€ in UK to 
724€ in Belgium and the cost per QALY was 20,111€ in 
Belgium, 18,882€ in France, 15,620€ in Switzerland, and
15,713€ in UK. Sensitivity analyses showed that all results were
robust under various assumptions. CONCLUSION: Consistent
results are found across the four countries with incremental cost-
effectiveness ratio below the acceptable thresholds, demonstrat-
ing that clopidogrel compared to aspirin is always cost-effective
in the studied population.
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OBJECTIVES: To determine the attributes of future anti-
coagulation drug candidates necessary to demonstrate cost-
effectiveness versus traditional warfarin therapy in the 
prevention of stroke and major bleeds in Atrial Fibrillation
(“AF”) patients. METHODS: A decision-analytic model was
constructed to simulate the population of individuals using war-
farin therapy versus a proxy (future) anticoagulation drug in
patients with AF. Exposure period, dosage and base case proba-
bilities for major bleeds and hepatotoxity were based on the war-
farin raw data from the Sportif III and V trials. The beneﬁts
associated with using warfarin therapy versus a proxy future
drug in patients with AF were quantiﬁed using the quality-
adjusted life year (QALY) framework. Univariate and multivari-
ate probabilistic sensitivity analyses using Bayesian second-order
Monte Carlo simulation were conducted. Hepatoxicity-related
risks were estimated pursuant to FDA’s usage of Hy’s Law.
RESULTS: The results of the base-case analysis demonstrate that
treatment with warfarin results in an expected cost $307 less
than treatment with a proxy future anticoagulant drug ($882.70
compared with $1189.90, respectively). The proxy drug proﬁle
is not cost effective (incremental cost-effectiveness ratio of
$960,000 per QALY) compared to warfarin. Warfarin dominates
treatment vs. the proxy drug with 84% probability. CONCLU-
SIONS: Recent new anticoagulant candidate drugs have not been
shown to be cost-effective compared to warfarin. To achieve
market acceptance, future anticoagulant drugs must be able to
demonstrate competitive cost, non-inferiority of stroke/major
bleed prevention and a superior safety proﬁle including reduc-
tion of hepatotoxicity risk.
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